CD274 and neoplasm: Furthermore, several issues remain unresolved in utilizing PD-L1 to guide immunotherapy: (1) determination of the cut-off value for PD-L1 positivity; (2) differences in results across various detection platforms; (3) variations in expression levels among different tumor types (Wojas-Krawczyk and Kubiatowski, 2020).